Exchange: NASDAQ·Updated 07:34 PM EDT
UPB logo

UPBUpstream Bio Inc.

$6.70
$0.16
(2.50%)
Today
Closed $6.57
$0.13
(1.98%)
After Hours
EarningsAug 5
Mkt Cap$348.83M
Vol320,722.00
News
all
press releases
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
More News
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage...
Yahoo! Finance: News
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of +39.00% and +2.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Upstream Bio (UPB) to Release Quarterly Earnings on Tuesday
Upstream Bio (NASDAQ:UPB) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat
Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) has been given an average rating of "Moderate Buy" by the five analysts that are covering the company, MarketBeat.com reports. One research analyst...
MarketBeat
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two h...
MarketBeat
Upstream Bio (NASDAQ:UPB) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen lowered shares of Upstream Bio from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line
Evercore downgraded shares of Upstream Bio from an "outperform" rating to an "in-line" rating and set a $15.00 target price on the stock. in a research note on Friday...
MarketBeat
Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data
Upstream Bio outlines Phase 3 plans for verekitug as asthma and CRSwNP data support dosing strategy; shares rise on update.read more...
Benzinga
<
1
2
>

Advertisement|Remove ads.